We are live on ! Find out more
ABBV icon

AbbVie

3,498 hedge funds and large institutions have $250B invested in AbbVie in 2024 Q3 according to their latest regulatory filings, with 242 funds opening new positions, 1,423 increasing their positions, 1,393 reducing their positions, and 71 closing their positions.

New
Increased
Maintained
Reduced
Closed

241% more first-time investments, than exits

New positions opened: 242 | Existing positions closed: 71

27% more call options, than puts

Call options by funds: $3.65B | Put options by funds: $2.87B

18% more funds holding in top 10

Funds holding in top 10: 178210 (+32)

15% more capital invested

Capital invested by funds: $217B → $250B (+$32.8B)

4% more funds holding

Funds holding: 3,3643,498 (+134)

2% more repeat investments, than reductions

Existing positions increased: 1,423 | Existing positions reduced: 1,393

0.23% more ownership

Funds ownership: 71.68%71.92% (+0.23%)

Holders
3,498
Holders Change
+134
Holders Change %
+3.98%
% of All Funds
50.23%
Holding in Top 10
210
Holding in Top 10 Change
+32
Holding in Top 10 Change %
+17.98%
% of All Funds
3.02%
New
242
Increased
1,423
Reduced
1,393
Closed
71
Calls
$3.65B
Puts
$2.87B
Net Calls
+$774M
Net Calls Change
+$88.2M
Name Holding Trade Value Shares
Change
Change in
Stake
FMLI
301
Fukoku Mutual Life Insurance
Japan
$48.3M
Pathstone Holdings
302
Pathstone Holdings
New Jersey
$47.9M -$484K -2,594 -1%
Northwestern Mutual Wealth Management
303
Northwestern Mutual Wealth Management
Wisconsin
$47.7M +$2.72M +14,595 +6%
CWM
304
CIBC World Markets
New York
$47.3M +$1.78M +9,523 +4%
VanEck Associates
305
VanEck Associates
New York
$47.3M +$4.71M +25,248 +11%
BFS
306
Bradley Foster & Sargent
Connecticut
$47.1M -$1.11M -5,938 -2%
NYLIM
307
New York Life Investment Management
New York
$46.6M -$1.39M -7,474 -3%
PCM
308
Polaris Capital Management
Massachusetts
$46.5M +$168K +900 +0.4%
FDCDDQ
309
Federation des caisses Desjardins du Quebec
Quebec, Canada
$46.2M +$145K +776 +0.3%
MOACM
310
Mutual of America Capital Management
New York
$46.2M -$1.07M -5,748 -2%
Temasek Holdings
311
Temasek Holdings
Singapore
$46.1M +$7.67M +41,093 +21%
PCH
312
Polar Capital Holdings
United Kingdom
$45.7M -$16.9M -90,321 -28%
CTC
313
Central Trust Company
Missouri
$45.3M -$879K -4,709 -2%
SMDAM
314
Sumitomo Mitsui DS Asset Management
Japan
$44.8M +$4.07M +21,790 +11%
TAM
315
Todd Asset Management
Kentucky
$44.8M -$32.1K -172 -0.1%
SAM
316
SP Asset Management
California
$44.6M +$223K +1,195 +0.5%
AWM
317
AE Wealth Management
Kansas
$44.6M -$5.55M -29,742 -12%
Daiwa Securities Group
318
Daiwa Securities Group
Japan
$44.4M +$3.98M +21,329 +10%
CS
319
Cannell & Spears
New York
$44.2M -$8.69M -46,578 -17%
ST
320
Sabal Trust
Florida
$43.9M -$37.9K -203 -0.1%
NAM
321
Nissay Asset Management
Japan
$43.4M +$492K +2,636 +1%
AAS
322
Avantax Advisory Services
Texas
$42.9M +$333K +1,782 +0.8%
DP
323
Dearborn Partners
Illinois
$42.3M -$1.01M -5,410 -2%
IMPI
324
Ilmarinen Mutual Pension Insurance
Finland
$42.3M
EB
325
Eastern Bank
Massachusetts
$41.9M +$14.7M +78,551 +59%

ABBV Hedge Fund Activity: Q3 2024 in Review

3,498 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2024, worth a combined $250B — up 15% from $217B a quarter earlier.

Buyers outnumbered sellers: 242 funds opened new ABBV positions and 71 closed out — a net gain of 171 holders — while 1,423 added to existing stakes and 1,393 trimmed.

The largest buyer was Capital World Investors, adding an estimated $964M. The largest seller was Franklin Resources, cutting an estimated $388M.

  • 3,498 institutional investors held AbbVie (ABBV) as of Q3 2024, up from 3,364 in Q2 2024.
  • Funds reported $250B of AbbVie stock for Q3 2024, up 15% quarter-over-quarter.
  • 242 funds opened new AbbVie positions in Q3 2024 and 71 closed out, a net change of +171 holders.
  • The largest AbbVie buyer in Q3 2024 was Capital World Investors, an estimated $964M added.
  • The largest AbbVie seller in Q3 2024 was Franklin Resources, an estimated $388M sold.

Based on aggregated 13F filings for Q3 2024.